This Article is no longer available, this page is showing similar articles.

Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

California Expands Oversight Of Private Equity In Healthcare With AB 1415 And SB 351

California Governor Gavin Newsom recently signed two significant pieces of legislation into law: Assembly Bill 1415 (AB 1415) and Senate Bill 351 (SB 351).

United States Healthcare

D

Dykema

FTC Switches Gears On Noncompetes: From Ban To Targeted Enforcement

The Federal Trade Commission (FTC) has changed its strategy on noncompete agreements, abandoning a wholesale prohibition for targeted enforcement.

United States Healthcare

MP

Manatt, Phelps & Phillips LLP

OIG Issues Advisory Opinion On Contributions To Charitable Foundations For Therapy Services

On September 11, 2025, the U.S. Department of Health and Human Services Office of Inspector General (the OIG) issued a favorable advisory opinion (AO 25-10 or the Opinion) regarding an arrangement...

United States Healthcare

WS

Winston & Strawn LLP

The PBM Effect: Regulatory And Market Implications For Life Sciences Companies And Healthcare Providers

Pharmacy Benefit Managers (PBMs) occupy a powerful and increasingly scrutinized position within the U.S. drug distribution and reimbursement system.

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

California Enacts Legislation Impacting Private Equity Investments In The Health Care Industry

United States Healthcare

BB

Bass, Berry & Sims

Governor Newsom Embraces Tighter Requirements On Private Equity And Hedge Fund Investments In California Health Care By Signing AB 1415 And SB 351

United States Healthcare

PL

Polsinelli LLP

This Time, California Governor Newsom Signs Private Equity Group And Hedge Fund Bills

United States Healthcare

M

Mintz

Update: Status Of FTC Case Against Three Largest PBMs

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

A $60 Billion Problem: Annual Medicare Losses Due To Fraud And Abuse

United States Healthcare

MS

Miller Shah

FDA Approves Celltrion's Aflibercept Biosimilar

United States Healthcare

GP

Goodwin Procter LLP

Colorado Limits Medicaid Coverage Of Definitive Drug Testing

United States Healthcare

PL

Polsinelli LLP

Ohio's PBM Regulation Passed By House Of Representatives

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

Benesch Healthcare+ Dialysis & Nephrology Digest No. 69

United States Healthcare

B

Benesch Friedlander Coplan & Aronoff LLP

Navigating Health Plan M&A: Strategies For Success In The Medicare Advantage Market (Podcast)

United States Healthcare

RG

Ropes & Gray LLP

See more

Webinars

See More

Recorded on 24 Jun 2025 | 3:00 PM

(2nd Session) 2025 Global In-House Counsel Survey Report: Unique Insights into the Global In-House Counsel Profession

IC

In-House Counsel Worldwide

Recorded on 24 Jun 2025 | 9:00 AM

(1st Session) 2025 Global In-House Counsel Survey Report: Unique Insights into the Global In-House Counsel Profession

IC

In-House Counsel Worldwide

Recorded on 30 Apr 2025 | 2:00 PM

Mondaq | 2025 Law Firm Data Landscape Report

mm

Mondaq

Recorded on 21 Jan 2025 | 3:00 PM

2025 Canadian In-House Counsel Report: Unparalleled Insights into Canada's In-House Profession from CCCA | Mondaq

TC

CBA In-House Lawyers

Highlighted Content

Plausibility At The EPO – An Update On G2/21

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In The United States Today?

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In Europe Today?

United States Healthcare

D

Dehns

How Good Does A Copy Need To Be?

United States Healthcare

D

Dehns

Supplementary Protection Certificates – European Patent Term Extensions

United States Healthcare

D

Dehns

How Much Experimental Data Is Needed For Patent Applications In Europe?

United States Healthcare

D

Dehns

The Silent Treatment: The EPO's Approach To Non-therapeutic Methods Encompassing Therapeutic Effects

United States Healthcare

D

Dehns

Implications Of The Genetic Technology (Precision Breeding) Bill On The Life Science IP Sector

United States Healthcare

D

Dehns

Protection For Plant Varieties In Europe And The UK Post-Brexit

United States Healthcare

D

Dehns

Best Practice For Invention Harvesting

United States Healthcare

D

Dehns

Food and Drugs Law

Conception & Inventorship Under Pharmaceutical Patent Law: Lessons And Best Practices

In patent law, conception is the cornerstone of inventorship. For pharmaceutical companies, where billions in revenue hinge on patents for molecules, formulations...

United States IP

UT

Upadhye Tang

Environmental Developments To Watch In New England

With an office in Boston, Beveridge & Diamond (B&D) closely tracks developments, upcoming deadlines, and business implications for companies with operations in Massachusetts...

United States Environment

BD

Beveridge & Diamond

Recent Federal Developments For October 2025

Monthly Federal Developments Memorandum

United States Environment

BC

Bergeson & Campbell

The PBM Effect: Regulatory And Market Implications For Life Sciences Companies And Healthcare Providers

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

Update On Texas Executive Order GA-56

United States Cannabis

BI

Buchanan Ingersoll & Rooney PC

Update: Status Of FTC Case Against Three Largest PBMs

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

FDA Approves Celltrion's Aflibercept Biosimilar

United States Healthcare

GP

Goodwin Procter LLP

Colorado Limits Medicaid Coverage Of Definitive Drug Testing

United States Healthcare

PL

Polsinelli LLP

Ohio's PBM Regulation Passed By House Of Representatives

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

See more

Life Sciences, Biotechnology & Nanotechnology

The PBM Effect: Regulatory And Market Implications For Life Sciences Companies And Healthcare Providers

Pharmacy Benefit Managers (PBMs) occupy a powerful and increasingly scrutinized position within the U.S. drug distribution and reimbursement system.

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

Amgen And Biocon Settle Denosumab BPCIA Case

On September 30, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab BPCIA litigation between Amgen...

United States IP

GP

Goodwin Procter LLP

FDA Approves Celltrion's Aflibercept Biosimilar

On October 9, 2025, the FDA approved Celltrion's aflibercept biosimilar, EYDENZELT® (aflibercept-boav) referencing Regeneron's EYLEA® (aflibercept).

United States Healthcare

GP

Goodwin Procter LLP

Ohio's PBM Regulation Passed By House Of Representatives

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

The New (And Politically Improved?) BIOSECURE Act

United States Healthcare

M

Mintz

FDCA: Fifth Circuit End-Run Suggests State Law Private Right Of Action

United States Healthcare

FL

Foley & Lardner

Advances In Plant Biotechnology Improving Health And Well-Being

United States IP

JA

J A Kemp LLP

BIOSECURE Included In Draft National Defense Authorization Act Of 2026

United States Healthcare

GP

Goodwin Procter LLP

EPO To Allow Color And Greyscale Patent Drawings: What U.S. Companies Need To Know

United States IP

BT

Barnes & Thornburg LLP

See more

Healthcare

Dealmaker's Digest: A Top 10 Bulletin - October 2025

In Dealmaker's Digest, read the top 10 latest developments in global transactions. We offer insights into M&A activity across industries and borders. To receive our M&A thought leadership, please join our mailing list.

United States Commercial

RG

Ropes & Gray LLP

Practical Implications Of Immigration Enforcement Activity On Benefit Plans – Part II

With the Trump Administration's continued emphasis on enforcement of U.S. immigration laws, employers are increasingly concerned about worksite raids.

United States Employment

FL

Foley & Lardner

California Expands Oversight Of Private Equity In Healthcare With AB 1415 And SB 351

California Governor Gavin Newsom recently signed two significant pieces of legislation into law: Assembly Bill 1415 (AB 1415) and Senate Bill 351 (SB 351).

United States Healthcare

D

Dykema

FTC Switches Gears On Noncompetes: From Ban To Targeted Enforcement

United States Healthcare

MP

Manatt, Phelps & Phillips LLP

OIG Issues Advisory Opinion On Contributions To Charitable Foundations For Therapy Services

United States Healthcare

WS

Winston & Strawn LLP

The PBM Effect: Regulatory And Market Implications For Life Sciences Companies And Healthcare Providers

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

California Enacts Legislation Impacting Private Equity Investments In The Health Care Industry

United States Healthcare

BB

Bass, Berry & Sims

Governor Newsom Embraces Tighter Requirements On Private Equity And Hedge Fund Investments In California Health Care By Signing AB 1415 And SB 351

United States Healthcare

PL

Polsinelli LLP

Shifting Trends In Healthcare Antitrust Enforcement: Navigating The Evolving Landscape

United States Anti-trust

AV

Axinn Veltrop & Harkrider

See more

Latest Videos

See more

Navigating Health Plan M&A: Strategies For Success In The Medicare Advantage Market (Podcast)

RG

Ropes & Gray LLP

Navigating Food And Dietary Supplements Labeling Litigation & Regulatory Hurdles In 2025 And Beyond (Video)

SM

Sheppard Mullin Richter & Hampton

Redefining Healthcare Leadership: Dr. Heather Farley On The Inaugural Role Of Chief Well-being Officer At MUSC (Video)

AM

Alvarez & Marsal

Navigating Women's Health With Rachel Welch (Video)

OK

Offit Kurman

Inside MedTech Translation Challenges: Ensuring Multilingual Regulatory Compliance

Moringside

Upcoming Events

WEST 25th Anniversary Celebration & Awards

United States Healthcare

FH

Foley Hoag LLP

Rewriting The Rules: How Physicians Can Win In Today's Market

United States Healthcare

HK

Holland & Knight

Adapting To An Evolving FDA: What Importers Need To Know And How To Prepare

United States Healthcare

DT

Diaz Trade Law

BIO On The Bayou

United States Healthcare

FH

Foley Hoag LLP

Tulane Innovation Institute Open MIC Night Pitch Competition

United States Healthcare

FH

Foley Hoag LLP

IP Watchdog Life Sciences Masters 2025

United States Healthcare

M

Mintz

26th Annual Pharmaceutical And Medical Device Ethics And Compliance Congress

United States Healthcare

SM

Sheppard Mullin Richter & Hampton

HCCA Healthcare Enforcement Compliance Conference

United States Healthcare

M

Mintz

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More